OVERVIEW

Brain health is recognized as an essential part of successful aging. To promote longevity and quality of life, brain functioning across cognitive, socio-emotional, and behavioral domains allows a person to realize their full potential over their lifetime. The prevalence of cognitive disorders is increasing rapidly as people live longer. Reducing the risk of cognitive disorders such as Alzheimer’s Disease and Related Dementias (ADRD) is as essential to the clinician as reducing hypertension and diabetes in reducing cardiovascular disease.
This course is designed to educate the practitioners and equip them with essential knowledge and state-of-the-art scientific methods to diagnose Alzheimer’s Disease and Related Dementias (ADRD) at its earliest stages and assist patients and their loved ones. Drawing on the presenters’ vast scientific and clinical expertise, the participants will be able to differentiate different cognitive syndromes and the etiological underpinnings of various clinical presentations. In addition, the participant will be familiarized with state-of-the-art neuropsychological and novel neuroimaging and plasma-based biomarkers methods to detect the earliest stages of Alzheimer’s Disease. This presentation will also provide essential information about emerging pharmacological agents in the treatment and management of Alzheimer’s Disease and Related Dementias, identifying the importance of cultural diversity and the importance of working with family members.  

LEARNING OBJECTIVES

Upon completion of this activity, participants will be able to:  

• Differentiate between normal cognitive aging, mild cognitive impairment (MCI), and clinical dementia;
• Discuss how to identify the underlying brain disorders causing clinical cognitive impairment in older adults;
• Identify the evidence-based, emerging brain biomarkers in cognitive disorders that help to diagnose at-risk older individuals for Alzheimer’s Disease and Related Dementias (ADRD);
• Identify the role of traditional and novel cognitive neuropsychological testing in early diagnosis of cognitive disorders in older individuals;
• Differentiate Alzheimer’s Disease from non- Alzheimer’s Disease pathology;
• Recognize those comorbid conditions that may result in differential treatment and outcomes in cognitively impaired older individuals;
• Describe pharmacological and nonpharmacological approaches to the treatment of Alzheimer’s Disease and Related Dementias (ADRD);
• List the emerging and promising agents in the treatment and management of early Alzheimer’s disease (AD);
• Explain the understanding of cross-cultural factors in the diagnosis and management of older individuals with Alzheimer’s Disease and Related Dementias (ADRD);
• Describe the promotion of brain health and longevity through evidence-based prevention.

ACCREDITATION

The University of Miami Leonard M. Miller School of Medicine designates these live winter activities for a maximum of 15 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. The Royal College of Physicians and Surgeons of Canada recognizes conferences and workshops held outside of Canada that are developed by a university, academy, hospital, specialty society or college as accredited group learning activities.

Through an agreement between the American Medical Association and the European Union of Medical Specialists, physicians may convert AMA PRA Category 1 Credit™ to an equivalent number of European CME Credits® (ECMECs®). Information on the process of converting AMA PRA Category 1 Credits™ to ECMECs® can be found at: www.eaccme.eu.

For more information please visit the official event page.